RE:RE:RE:Discussions Involve Multiple Partners in Varying Formatsdont forget about the DPP4 inhibitors and apparently GLP-1 receptor agonists.
Over at agora Bear speculates "Resverlogix has probably filed similar patents for apabetalone in combo with DPP4 inhibitors and GLP-1 receptor agonists, with which Resverlogix has also dropped hints that there was synergy with apabetalone."
same questions for SGLT's/DPP4s/GLP as for statins: Are all SGLT's/DPP4s/GLP's created equal? Or do we see more synergy with one than the other? Or all with 1 and none for all, or something like that? Would certainly help our case if we can help elevate 1 of each of these over their competitors...
sounds like a buyout, if in play, would NOT unleash the kraken. we wouldn't get near what we deserve. dont know why the focus only on SGLT's though...no mention of DPP4 or GPL agonists moving fwd it seems....
"Multiple partners, multiple formats": maybe we'd be best served if we licensed dirty-ole 208 to 1 SGLT company, 1 DPP4 company, 1 GLP agonists company, etc. Why restrict ourselves to 1 drug? or even 1 drug CLASS? unheard of that you can pair up 1 drug with so many different CLASSES of other drugs... unless some BP is gonna hand over 10-14B, which isnt looking likely, the only way we're gonna unlock the money is via our own SP......announce a fat deal, leaving us as a viable company with a war chest to kick off the other 12 compounds in waiting. lets truly BE the world leader in BET for CV and allllllllllllll the other indications we've been talking about for YEARS.
for some reason im fixated on 10 Billlllliion dollar dollar bills y'all. thats the expectation that DM put in my head a long time ago with the corporate presentations about market cap for like-minded drugs (tunrs out they weren't like minded as we're the only one that thinks like this!!). Those estimates were for single-purpose, single effect drugs, not like our MULTI-EFFECT WONDERBREAD!!!. 14B for ezalutamide (sp?), so anywhere between 10B and 14B is my expectation. it only goes up from there based on additional indications and synergies with other drugs. I dont think BP can afford to buy out what we'd really be worth if we can only unlock the POTENTIAL. a big fat juicy deal, coupled with a move onto the NASDAQ would really juice the results. i think the NASDAQ discussion is pretty much dead in the water though, so that would be a very welcome surprise....
we seem to have hit a brick wall around 1.30. better not be for a $hit financing....
go rvx go....new daddy needs a new pair of...EVERYTHING!